Recently, Colum Pharmaceutical's Osteotriol soft capsule was approved for listing, Tagolizumab first-line indications declared NDA, and the latest research results of Lukang Sartuzumab were announced ...... So far this year, Colum Pharmaceuticals has had 6 varieties approved for listing, with a cumulative total of 137 varieties under review (45 first), and 26 varieties ready for the 10th batch of collection and procurement. At present, the company has 35 new drugs (21 category 1 new drugs) in the declaration of clinical and above the research and development stage; 66 new classified reported product varieties in the review, 18 temporarily no first generic approved.
On May 27, NMPA official website shows that Kelen Pharmaceuticals to generic 4 class reported production of osteotriol soft capsule was approved for production and deemed to be over-assessed, for the sixth domestic. Osteotriol soft capsule is an active vitamin D3 analogue, for the national medical insurance class B varieties. MiNe data show that in 2023, China's urban public hospitals, county-level public hospitals, urban community centres and township health centres (referred to as China's public healthcare institutions) terminal osteotriol soft capsule sales of more than 700 million yuan.
So far this year, Coren Pharmaceuticals has six varieties approved for production and deemed to be over-rated, including Osteotriol Soft Capsules, Compound Amino Acid Injection (18AA-VII), Piracetam Injection, Olaparib Tablets, Eltrombopag olamine tablets, and Omega-3 Triglyceride (2%) Medium/Long Chain Fatty Lactose/Amino Acid (16)/Dextrose (16%) Injection.